SV-101 / Syncromune - LARVOL DELTA

Cryo-immune vaccination (CIV) by SYNC-T therapy: Preclinical modeling of a novel device-multidrug immunotherapeutic approach to eradicate advanced metastatic cancers (AACR 2024) - "As a starting point, allometric scaling was used to model dosing analogous to the proprietary ICT drug formulations SV-101 and SV-102 in clinical testing (Syncromune, Inc.). To gain initial mechanistic insights, responses will be compared in host mice that are genetically deficient in selected components of the adaptive or innate immune systems. Progress in methodological and mechanistic studies will be presented."

IO biomarker • Late-breaking abstract • Metastases • Preclinical • Breast Cancer • Oncology • Solid Tumor • CD40LG • CTLA4

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Williams Cancer Foundation | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Breast Cancer • Lung Cancer • Oncology • Solid Tumor

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Williams Cancer Foundation | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Lung Cancer • Oncology • Solid Tumor